Analysts forecast that Neuronetics Inc (NASDAQ:STIM) will post sales of $14.69 million for the current quarter, Zacks reports. Two analysts have issued estimates for Neuronetics’ earnings. The highest sales estimate is $14.71 million and the lowest is $14.68 million. The business is expected to report its next quarterly earnings report on Tuesday, February 5th.
According to Zacks, analysts expect that Neuronetics will report full-year sales of $51.83 million for the current financial year, with estimates ranging from $51.82 million to $51.85 million. For the next financial year, analysts anticipate that the business will post sales of $62.74 million, with estimates ranging from $62.30 million to $63.17 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover Neuronetics.
Neuronetics (NASDAQ:STIM) last announced its quarterly earnings data on Tuesday, November 6th. The company reported ($0.29) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.40) by $0.11. The company had revenue of $13.74 million during the quarter, compared to the consensus estimate of $12.68 million.
Shares of STIM stock opened at $18.54 on Wednesday. The company has a current ratio of 7.63, a quick ratio of 7.46 and a debt-to-equity ratio of 0.33. Neuronetics has a fifty-two week low of $15.40 and a fifty-two week high of $39.39.
Institutional investors have recently made changes to their positions in the stock. American International Group Inc. bought a new position in shares of Neuronetics during the third quarter valued at approximately $136,000. Victory Capital Management Inc. bought a new position in shares of Neuronetics during the second quarter valued at approximately $133,000. Pier Capital LLC bought a new position in shares of Neuronetics during the second quarter valued at approximately $186,000. Teachers Advisors LLC bought a new position in shares of Neuronetics during the third quarter valued at approximately $267,000. Finally, Engineers Gate Manager LP bought a new position in shares of Neuronetics during the third quarter valued at approximately $284,000. Institutional investors own 69.16% of the company’s stock.
Neuronetics Company Profile
Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders. It offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment for adult patients with major depressive disorder. The company's NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed MRI-strength magnetic field, which induces electrical currents designed to stimulate specific areas of the brain associated with mood.
Featured Article: What is Liquidity?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.